Phase I Multidose-Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous Infusion Every 3 Weeks to Patients With Relapsed/Refractory B-C...

nork Younes, Anas, Kim, Stella, Romaguera, Jorge, Copeland, Amanda, Farial, Silvana de Castro, Kwak, Larry W., Fayad, Luis, Hagemeister, Frederick, Fanale, Michelle, Neelapu, Sattva, Lambert, John M., Morariu-Zamfir, Rodica, Payrard, Sandrine, Gordon, Leo I.
Argitaratua izan da J Clin Oncol (2012)